Parambir Dulai
Parambir Dulai
在 health.ucsd.edu 的電子郵件地址已通過驗證
標題
引用次數
引用次數
年份
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis
PS Dulai, S Singh, J Patel, M Soni, LJ Prokop, Z Younossi, G Sebastiani, ...
Hepatology 65 (5), 1557-1565, 2017
9322017
Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis
R Khera, MH Murad, AK Chandar, PS Dulai, Z Wang, LJ Prokop, ...
Jama 315 (22), 2424-2434, 2016
5712016
Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease
R Loomba, V Seguritan, W Li, T Long, N Klitgord, A Bhatt, PS Dulai, ...
Cell metabolism 25 (5), 1054-1062. e5, 2017
4852017
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice
PS Dulai, CB Sirlin, R Loomba
Journal of hepatology 65 (5), 1006-1016, 2016
2462016
The real-world effectiveness and safety of vedolizumab for moderate–severe Crohn’s disease: results from the US VICTORY consortium
PS Dulai, S Singh, X Jiang, F Peerani, N Narula, K Chaudrey, ...
Official journal of the American College of Gastroenterology| ACG 111 (8 …, 2016
2362016
Natural history of adult ulcerative colitis in population-based cohorts: a systematic review
M Fumery, S Singh, PS Dulai, C Gower-Rousseau, L Peyrin-Biroulet, ...
Clinical Gastroenterology and Hepatology 16 (3), 343-356. e3, 2018
1932018
Natural history of adult ulcerative colitis in population-based cohorts: a systematic review
M Fumery, S Singh, PS Dulai, C Gower-Rousseau, L Peyrin-Biroulet, ...
Clinical Gastroenterology and Hepatology 16 (3), 343-356. e3, 2018
1932018
Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes
S Singh, PS Dulai, A Zarrinpar, S Ramamoorthy, WJ Sandborn
Nature reviews Gastroenterology & hepatology 14 (2), 110-121, 2017
1792017
Risks of serious infection or lymphoma with anti–tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review
PS Dulai, KD Thompson, HB Blunt, MC Dubinsky, CA Siegel
Clinical Gastroenterology and Hepatology 12 (9), 1443-1451, 2014
1422014
Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease
S Singh, NS Ding, KL Mathis, PS Dulai, AM Farrell, JH Pemberton, ...
Alimentary pharmacology & therapeutics 42 (7), 783-792, 2015
1202015
Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management
PS Dulai, WJ Sandborn, S Gupta
Cancer prevention research 9 (12), 887-894, 2016
1072016
Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD
PS Dulai, CA Siegel, JF Colombel, WJ Sandborn, L Peyrin-Biroulet
Gut 63 (12), 1843-1853, 2014
1062014
Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases
C Abraham, PS Dulai, S Vermeire, WJ Sandborn
Gastroenterology 152 (2), 374-388. e4, 2017
1052017
Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis
M Fumery, PS Dulai, S Gupta, LJ Prokop, S Ramamoorthy, WJ Sandborn, ...
Clinical Gastroenterology and Hepatology 15 (5), 665-674. e5, 2017
982017
First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis
S Singh, MH Murad, M Fumery, PS Dulai, WJ Sandborn
Clinical Gastroenterology and Hepatology 18 (10), 2179-2191. e6, 2020
902020
Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium
N Narula, F Peerani, J Meserve, G Kochhar, K Chaudrey, J Hartke, ...
The American journal of gastroenterology 113 (9), 1345, 2018
882018
Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis
S Singh, A Facciorusso, PS Dulai, V Jairath, WJ Sandborn
Clinical Gastroenterology and Hepatology 18 (1), 69-81. e3, 2020
852020
A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables
CA Siegel, H Horton, LS Siegel, KD Thompson, T Mackenzie, SK Stewart, ...
Alimentary pharmacology & therapeutics 43 (2), 262-271, 2016
852016
Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease
PS Dulai, MW Gleeson, D Taylor, SD Holubar, JC Buckey, CA Siegel
Alimentary pharmacology & therapeutics 39 (11), 1266-1275, 2014
722014
Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease
PS Dulai, BS Boland, S Singh, K Chaudrey, JL Koliani-Pace, G Kochhar, ...
Gastroenterology 155 (3), 687-695. e10, 2018
702018
系統目前無法執行作業,請稍後再試。
文章 1–20